{"entity":{"id":"nct06420089","kind":"trial","name":"CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)","aka":[],"tldr":"A phase 1 trial of Senza5 CART5 run by Vittoria Biotherapeutics, now recruiting.","summary":"CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL) is a phase 1 interventional study registered as NCT06420089 by Vittoria Biotherapeutics, with 30 participants planned, started 2024-10-04. Conditions recorded: T Cell Non-Hodgkin Lymphoma. Interventions recorded: Senza5 CART5.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06420089","url":"https://clinicaltrials.gov/study/NCT06420089"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["viper-101"],"companies":["vittoria-biotherapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06420089","phase":"1","setting":"CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) to Enhance Immunotherapy Against T Cell Non-Hodgkin Lymphoma (NHL): a First-in-human Phase I Clinical Trial","sponsor":"Vittoria Biotherapeutics","enrolled":30,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06420089/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"viper-101","kind":"drug","name":"Senza5 CART5","route":"/drugs/viper-101/"}],"company":[{"id":"vittoria-biotherapeutics","kind":"company","name":"Vittoria Biotherapeutics","route":"/companies/vittoria-biotherapeutics/"}]}}